INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
15.93 USD
-0.19 (-1.18%)
15.93 USD
0 (0%)
IART gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year IART was profitable.
IART had a positive operating cash flow in the past year.
Of the past 5 years IART 4 years were profitable.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART's Return On Assets of -13.65% is in line compared to the rest of the industry. IART outperforms 56.08% of its industry peers.
The Return On Equity of IART (-48.20%) is comparable to the rest of the industry.
With a decent Return On Invested Capital value of 4.68%, IART is doing good in the industry, outperforming 76.19% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 9.01%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROIC | 4.68% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
The Operating Margin of IART (9.46%) is better than 77.25% of its industry peers.
IART's Operating Margin has declined in the last couple of years.
IART's Gross Margin of 57.24% is in line compared to the rest of the industry. IART outperforms 55.56% of its industry peers.
In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
IART has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
IART has less shares outstanding than it did 1 year ago.
IART has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, IART has a worse debt to assets ratio.
2.2 Solvency
IART has an Altman-Z score of 1.10. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.10, IART is in line with its industry, outperforming 51.32% of the companies in the same industry.
IART has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
IART has a worse Debt to Equity ratio (1.18) than 78.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.1 |
ROIC/WACC0.77
WACC6.08%
2.3 Liquidity
IART has a Current Ratio of 1.23. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
IART has a worse Current ratio (1.23) than 80.42% of its industry peers.
IART has a Quick Ratio of 1.23. This is a bad value and indicates that IART is not financially healthy enough and could expect problems in meeting its short term obligations.
IART has a worse Quick ratio (0.73) than 86.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
The earnings per share for IART have decreased strongly by -20.85% in the last year.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 3.53%.
The Revenue has been growing slightly by 1.20% on average over the past years.
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
3.2 Future
IART is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.21% yearly.
The Revenue is expected to grow by 3.88% on average over the next years.
EPS Next Y-11.85%
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.11, the valuation of IART can be described as very cheap.
IART's Price/Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 97.35% of the companies in the same industry.
IART is valuated cheaply when we compare the Price/Earnings ratio to 27.08, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 6.46, the valuation of IART can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 98.41% of the companies listed in the same industry.
IART's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.09.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 6.46 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 92.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.3 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
5. Dividend
5.1 Amount
IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.93
-0.19 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.73%
Inst Owner Change-1.14%
Ins Owners3.04%
Ins Owner Change1.47%
Market Cap1.24B
Revenue(TTM)1.62B
Net Income(TTM)-500626000
Analysts54.12
Price Target16.76 (5.21%)
Short Float %10%
Short Ratio6.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.27%
Min EPS beat(2)-6.76%
Max EPS beat(2)2.22%
EPS beat(4)3
Avg EPS beat(4)2.45%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)-0.11%
EPS beat(12)6
Avg EPS beat(12)3.26%
EPS beat(16)8
Avg EPS beat(16)3.79%
Revenue beat(2)1
Avg Revenue beat(2)0.78%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-0.95%
Revenue beat(12)2
Avg Revenue beat(12)-0.82%
Revenue beat(16)3
Avg Revenue beat(16)-0.75%
PT rev (1m)0%
PT rev (3m)-1.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.11 | ||
| Fwd PE | 6.46 | ||
| P/S | 0.77 | ||
| P/FCF | N/A | ||
| P/OCF | 17.51 | ||
| P/B | 1.19 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.3 |
EPS(TTM)2.24
EY14.06%
EPS(NY)2.47
Fwd EY15.49%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.91
OCFY5.71%
SpS20.82
BVpS13.33
TBVpS-9.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number25.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROCE | 5.61% | ||
| ROIC | 4.68% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 18.86% | ||
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 79.68% | ||
| Cap/Sales | 7.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 23.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.1 |
F-Score5
WACC6.08%
ROIC/WACC0.77
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
EPS Next Y-11.85%
EPS Next 2Y-1.83%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
EBIT growth 1Y-36.46%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.98%
EBIT Next 3Y9.96%
EBIT Next 5YN/A
FCF growth 1Y-130.53%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-65.94%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 3 / 10 to IART.
Can you provide the valuation status for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
How profitable is INTEGRA LIFESCIENCES HOLDING (IART) stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 2 / 10.